Why Ophthotech Corp. Shares Skyrocketed

Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.

What: Shares of Ophthotech , a clinical-stage biopharmaceutical company focused on developing therapies to treat diseases of the back of the eye, roared higher by as much as 24% after announcing a licensing deal for lead experimental compound Fovista with Novartis .

So what: Under the terms of the deal Ophthotech will retain all rights to Fovista within the United States with Novartis licensing the rights to the wet age-related macular degeneration drug hopeful in all other countries. The deal itself could be worth more than $1 billion in milestone and royalty payments for Ophthotech, with the company expected to receive a $200 million upfront free, as well as an additional $130 million in near-term enrollment milestone payments. The remaining milestones are comprised of $300 million in ex-U.S. approval milestones, and $400 million in ex.-U.S. sales milestones. Initial top-line data from its trial involving fovista is expected to be available sometime in 2016.

Now what: Clearly Novartis must've liked what it saw, otherwise they wouldn't have dropped a whopping $200 million upfront on Ophthotech. The wet-AMD market is expected to be a huge growth driver around the world as life expectancies continue to increase, giving wet-AMD drugs and drug hopefuls plenty of opportunity to improve patient quality of life, and make a pretty penny along the way. While this deal certainly alleviates any concerns about its funding for a long time, I'd remind investors that the company also mentioned It's two years away from even reporting its top-line phase 3 data. This means two years with very few catalysts for a clinical-stage company already valued at $1.3 billion. With that being said, it might be wise to stick to the sidelines here until we get a sizable pullback.

Ophthotech shares may have soared today, but it'll likely be hard-pressed to keep pace with this top stock over the long run
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.

The article Why Ophthotech Corp. Shares Skyrocketed originally appeared on Fool.com.

Sean Williams has no material interest in any companies mentioned in this article. You can follow him on CAPS under the screen name TMFUltraLong, track every pick he makes under the screen name TrackUltraLong, and check him out on Twitter, where he goes by the handle @TMFUltraLong.Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story